Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on developing elraglusib, a small molecule that inhibits GSK-3β, an enzyme cancer cells rely on to survive and grow. By blocking GSK-3β, elraglusib aims to reduce tumor cell proliferation, promote cancer cell death, modulate immune response, and reduce tumor fibrosis. The lead program uses elraglusib via IV injection in combination with standard chemotherapy (gemcitabine/nab-paclitaxel) to treat first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), a cancer with a 5-year survival rate under 5% for Stage IV patients. The Phase 2 trial met its primary endpoint, showing median overall survival of 10.1 months vs. 7.2 months in the control arm, with Actuate planning FDA and EMA discussions in 2026 to design a Phase 3 registration study. Beyond mPDAC, elraglusib is in early-stage development for pediatric cancers including Ewing sarcoma and neuroblastoma, and Actuate is developing an oral tablet formulation targeting additional solid tumor indications. Actuate generates no product revenue and funds operations through equity financing. The company's strategy is to advance elraglusib through Phase 3 in mPDAC and, if approved, either commercialize independently in the U.S. or partner with a larger pharma company. Actuate holds Fast Track and Orphan Drug designations from the FDA, owns or licenses 119 patents globally with U.S. composition-of-matter patents expiring in 2038, and operates with only 12 full-time employees by outsourcing clinical, manufacturing, and regulatory functions.